Chemomab Therapeutics Statistics
Total Valuation
CMMB has a market cap or net worth of $16.49 million. The enterprise value is $927,003.
| Market Cap | 16.49M |
| Enterprise Value | 927,003 |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, before market open.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CMMB has 14.72 million shares outstanding.
| Shares Outstanding | 14.72M |
| Owned by Insiders (%) | 14.97% |
| Owned by Institutions (%) | 23.83% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.00 |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.24 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.83, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.83 |
| Quick Ratio | 3.83 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -109.90% and return on invested capital (ROIC) is -149.10%.
| Return on Equity (ROE) | -109.90% |
| Return on Assets (ROA) | -83.70% |
| Return on Capital (ROIC) | -149.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$966,800 |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -21,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.65% in the last 52 weeks. The beta is 0.20, so CMMB's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -17.65% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 0.75 |
| Relative Strength Index (RSI) | 57.08 |
| Average Volume (20 Days) | 40,235 |
Short Selling Information
| Short Interest | 100,465 |
| Short Previous Month | 99,698 |
| Short % of Shares Out | 0.71% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.84 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.46M |
| Pretax Income | -19.36M |
| Net Income | -19.34M |
| EBITDA | n/a |
| EBIT | -19.36M |
| Earnings Per Share (EPS) | -$1.56 |
Balance Sheet
The company has $15.95 million in cash and $390,000 in debt, giving a net cash position of $15.56 million or $1.06 per share.
| Cash & Cash Equivalents | 15.95M |
| Total Debt | 390,000 |
| Net Cash | 15.56M |
| Net Cash Per Share | $1.06 |
| Equity (Book Value) | 13.33M |
| Book Value Per Share | 0.91 |
| Working Capital | 12.44M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CMMB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.58% |
| Shareholder Yield | -28.58% |
| Earnings Yield | -117.27% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CMMB is $5.67, which is 406.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.67 |
| Price Target Difference | 406.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -53.27% |
Stock Splits
The last stock split was on March 17, 2021. It was a reverse split with a ratio of 1:16.
| Last Split Date | Mar 17, 2021 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |